Drilldown: Medicines
Appearance
Medicines > onset
:
BP effect within hours (oral); 5-10 minutes (IV)
or
Clinical improvement within 24-72 hours
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
:
BP effect within hours (oral); 5-10 minutes (IV)
or
Clinical improvement within 24-72 hours
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
Use the filters below to narrow your results.
[[:Category:Antifungals|Antifungal (triazole)]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Azalides|Azalide]] (1) ·
[[:Category:Beta blockers|Combined alpha-1 and non-selective beta blocker]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:Macrolide_antibiotics|Macrolide antibiotic]] (1) ·
[[:Category:Triazoles|Triazole]] (1)
None (3) ·
'"`UNIQ--vote-00000015-QINU`"' The favorable pregnancy safety profile and the dual mechanism support its first-line role in pregnancy-associated hypertension and in hypertensive emergencies where rapid, controllable BP reduction is needed'"`UNIQ--ref-00000016-QINU`"'. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-000003F6-QINU`"', '"`UNIQ--vote-000003F7-QINU`"', '"`UNIQ--vote-000003F8-QINU`"', '"`UNIQ--vote-000003F9-QINU`"', '"`UNIQ--vote-000003FA-QINU`"', '"`UNIQ--vote-000003FB-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5 (1) ·
Oral: 100 mg PO BID, titrate to 400 mg BID. IV: 20 mg over 2 minutes, repeat 40-80 mg every 10 minutes as needed (maximum cumulative 300 mg); continuous infusion 2 mg/minute (1) ·
Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
250 mg, 500 mg, 600 mg tablets; 100, 200 mg/5 mL suspension; 2 g ER suspension (Zmax); 500 mg IV (1) ·
5 mg tablets; combination with metformin (1) ·
50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) ·
Tablets 100, 200, 300 mg; injection 5 mg/mL (1)
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) ·
~6-8 hours'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~68 hours (terminal; reflects deep tissue accumulation, much longer than plasma)'"`UNIQ--ref-000003FC-QINU`"' (1)
>90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) ·
~25% (oral; extensive first-pass)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
None (1) ·
'''Among the safest antihypertensives in pregnancy''', recommended for chronic hypertension during pregnancy and first-line for severe hypertension in preeclampsia and eclampsia'"`UNIQ--ref-0000001C-QINU`"' (1) ·
Generally considered safe; commonly used in pregnancy when macrolide indicated.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 5 results in range #1 to #5.

